New York, New York–(Newsfile Corp. – May 25, 2026) – Levi & Korsinsky notifies investors that it has commenced an investigation into Regeneron Pharmaceuticals, Inc. (“Regeneron Pharmaceuticals, Inc.”) (NASDAQ: REGN) concerning potential violations of the federal securities laws.
In March, the Senior Vice President of Investor Relations, Ryan Crowe, told investors management was “hopeful” for the LAG-3 study to show positive differentiators for Fianlimab in combination with Libtayo, such as a low to mid-teens median PFS” and an “opportunity to have a statistically significant, clinically meaningful benefit on OS.”
A little more than two months later, on May 16, 2026, Regeneron disclosed that fianlimab + Libtayo did not meet the trial’s primary endpoint against Keytruda. The upbeat language on potential outcomes offered on March 10, 2026 failed to stress the risk of the trial failure….
Request a free credit report once a year from bureaus like TransUnion or Experian to ensure no one has opened fraudulent loans or store accounts in your name without your knowledge.